OncoMatch/Clinical Trials/NCT06129747
Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
Is NCT06129747 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for breast cancer.
The standard treatment for participants whose cancer has returned after breast conserving surgery is radiation given twice daily (separated by at least 6 hours) for a total of 30 treatments. The purpose of this study is to find out if giving radiation once a day for 15 treatments after repeat breast conserving surgery works as well as giving it the standard way.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Excluded: BRCA1 mutation
Excluded: BRCA2 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: radiation therapy — whole breast irradiation
Three years of time must have elapsed since the end of the last course of whole breast irradiation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center · Cleveland, Ohio
- Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center · Cleveland, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06129747 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received radiation therapy.
Are patients with BRCA1 alterations eligible?
No. BRCA1 mutation is an exclusion criterion.
Are patients with BRCA2 alterations eligible?
No. BRCA2 mutation is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages